Pralatrexate-13C5

CAS : 146464-95-1

Ref. TR-P700502

Informations sur le produit

• Nom: Pralatrexate-13C5
• Synonymes: N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-L-glutamic Acid-13C5, N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-L-glutamic Acid-13C5, 10-Propargyl-10-deazaaminopterin-13C5, Folotyn-13C5, PDX-13C5, <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-, <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-, Folotyn, N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-<span class="text-smallcaps">L</span>-glutamic acid, N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid, NSC 754230, Pralatrexate

Description

Applications Pralatrexate-15C5 is labelled Pralatrexate (P700500) which is an antifolate with high affinity for the reduced folate carrier-type 1 that produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
References Krug, L.M. et al.: Clin. Cancer Res., 6, 3493 (2000); O'Connor, O.A. et al.: Br. J. Haematol., 139, 425 (2007); O'Connor, O.A. et al.: J. Clin. Oncol., 29, 1182 (2011)

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 492.472
• Formule: C₁₈C₅H₂₃N₇O₅
• Couleur/Forme: Neat
• InChI: InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/i8+1,9+1,16+1,17+1,22+1
• Code InChI: InChIKey=VNWKTOKETHGBQD-UHFFFAOYSA-N
• SMILES: C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[15C@@H]([15CH2][15CH2][15C](=O)O)[15C](=O)O)cc1